Similar articles

• [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].

  Kiseleva AM, Zlydnikov DM, Mazhinskaia VP, Lebedeva VK, Zakharova NG. Kiseleva AM, et al. Zh Nevropatol Psikhiatr Im S S Korsakova. 1973;73(4):530-4. Zh Nevropatol Psikhiatr Im S S Korsakova. 1973. PMID: 4705408 Clinical Trial. Russian. No abstract available.
• Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial.

  Appleton DB, Eadie MJ, Sutherland JM. Appleton DB, et al. Med J Aust. 1970 Oct 3;2(14):626-9. Med J Aust. 1970. PMID: 4920572 Clinical Trial. No abstract available.
• Amantadine therapy in parkinsonism.

  Forssman B, Kihlstrand S, Larsson LE. Forssman B, et al. Acta Neurol Scand. 1972;48(1):1-18. doi: 10.1111/j.1600-0404.1972.tb07524.x. Acta Neurol Scand. 1972. PMID: 4553409 Clinical Trial. No abstract available.
• [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].

  Dupont E. Dupont E. Ugeskr Laeger. 1973 Jan 15;135(3):116-22. Ugeskr Laeger. 1973. PMID: 4567942 Review. Danish. No abstract available.
• [Review of current pharmacotherapy of Parkinsonism. Comprehensive review].

  Benesová O. Benesová O. Cesk Neurol. 1973 May;36(3):196-205. Cesk Neurol. 1973. PMID: 4574253 Review. Czech. No abstract available.